Cargando…
Rapid progression of disease from immunotherapy following targeted therapy: insights into treatment management and sequence
With emerging promising therapeutic regimens in non-small cell lung cancer (NSCLC), the standard-of-care treatments for a variety of histologic and mutated subgroups in NSCLC has been regularly shifting in response to landmark clinical trials. However, with the availability of a range of therapeutic...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
AME Publishing Company
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7578509/ https://www.ncbi.nlm.nih.gov/pubmed/33145086 http://dx.doi.org/10.21037/jtd.2019.08.14 |